Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone produced primarily by the adrenal glands, with additional synthesis in the gonads and brain. It serves as a metabolic intermediate in the biosynthesis of androgen and estrogen sex steroids. DHEA acts as a precursor to testosterone and estrogen and has weak intrinsic androgenic and estrogenic activity. It also functions as a neurosteroid with modulatory effects on neurotrophic factor receptors in the central nervous system[5]. Synthetic DHEA is available as an over-the-counter dietary supplement (in the US) or prescription medication (prasterone), used for conditions such as vaginal atrophy, adrenal insufficiency, depression, osteoporosis/low bone mineral density in postmenopausal women, sexual dysfunction (especially hypoactive sexual desire disorder), infertility adjunctive therapy before IVF cycles, lupus (as a steroid-sparing agent), and possibly for mood disorders[1][2][3][5][6]. Its use for anti-aging or athletic performance enhancement lacks robust evidence; most studies show little benefit for muscle strength or physical performance[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dehydroepiandrosterone.